

EUROCANPLATFORM WORKPACKAGE 11 CLINICAL EPIDEMIOLOGY

Masoud Babaei, MD
dkfz



DEUTSCHES
KREBSFORSCHUNGSZENTRUM
IN DER HELMHOLTZ-GEMEINSCHAFT




50 Jahre – Forschen für
ein Leben ohne Krebs


EurocanPlatform

work package 11 projects,

is a consortium of major European cancer centers aimed at enhanced translation of progress in oncological research into clinical practice



Translational cancer research – a coherent research continuum



EurocanPlatform WP11 5th Annual meeting

Frankfurt airport, December 2015



Participating centers

Clinical cancer registries from 5 European countries

- ***Population-based registries:***

- Netherlands National Cancer Registry (NNCR), Netherlands
- Swedish Colorectal Cancer Registry (SCRCR), Sweden
- Norwegian Cancer Registry (NCR), Norway

- ***Institute-based registries:***


- Institute Jules Bordet (IJB) in Brussels, Belgium
- Netherlands Cancer Institute (NKI) in Amsterdam, **Netherlands**
- Portuguese Institute of Oncology in Porto (IPO-Porto), Portugal

Eurocan collaborative projects:

- ☐ Cancer registry build-up efforts in Europe, for colorectal and breast cancers.
- ☐ Application of laparoscopic surgery in colorectal cancer patients in Europe.
 1. Minimally invasive [colon cancer](#) surgery in Europe: Implementation and outcomes (coming soon).
 2. Minimally invasive [rectal cancer](#) surgery in Europe: Implementation and outcomes (coming soon).
- ☐ Administration of adjuvant chemotherapy in stage II/III colon cancer in Europe.
- ☐ Administration of neoadjuvant therapy in rectal cancer patients in Europe.
- ☐ A comparison of patient populations, surgical resection rates, and short term outcomes among patients with pancreatic cancer as a study among EUROCAN Platform members

Survival analysis

PanGenEU project



Five-Year RS of Pancreatic Cancer According to Stage, Morphology, and Anatomic Sub site for Patients Aged 15 to 74 Years, Diagnosed in 2002 to 2010 in Germany and the United States, Period of Estimation 2007 to 2010

Variable	Germany		United States	
	n (%)	5-y RS (SE)	n (%)	5-y RS (SE)
Stage*				
Localized	470 (3.9) [†]	43.7 (3.7)	1718 (7.2) [†]	41.5 (1.9)
Regional	4011 (33.3) [†]	16.7 (1.1)	7336 (31.9) [†]	14.4 (0.7)
Distant	7567 (62.8) [†]	4.3 (0.4)	13581 (60.8) [†]	3.7 (0.3)
Unknown	10,380	11.2 (0.6)	1269	11.6 (1.6)
Morphology*				
Endocrine (all)	862 [‡]	50.7 (2.7)	1347	49.0 (2.4)
Male	464 (53.8)	47.7 (3.7)	748 (55.5)	47.4 (3.2)
Female	398 (46.2)	53.7 (4.1)	599 (44.5)	51.6 (3.7)
Exocrine (all)	21,523	8.4 (0.4)	22,441	7.2 (0.3)
Male	12,369 (57.5)	7.8 (0.5)	12,356 (55.1)	6.3 (0.4)
Female	9154 (42.5)	9.2 (0.6)	10,085 (44.9)	8.3 (0.5)
Subsite (ICD-10)*				
Head (C25.0)	11,551 (51.5)	11.1 (0.6)	11,532 (48.2)	9.8 (0.5)
Body (C25.1)	1788 (8.0)	11.5 (1.4)	2608 (10.9)	6.7 (0.9)
Tail (C25.2)	2499 (10.9)	13.8 (1.3)	3080 (12.9)	14.2 (1.0)
Islets of Langerhans (C25.4)	133 (0.6)	68.1 (6.2)	322 (1.4)	62.0 (4.8)
Overlapping lesions (C25.8)	721 (3.2)	8.9 (2.0)	1791 (7.5)	7.9 (1.1)
Pancreas, NOS (C25.9)	5679 (25.3)	6.7 (0.6)	4148 (17.4)	6.3 (0.7)

Variable	2002–2004		2005–2007		2008–2010		Diff.	P†
	5-y RS	SE	5-y RS	SE	5-y RS	SE		
Overall*	9.6	0.3	10.8	0.3	12.1	0.3	2.5	<0.0001
Age group, y								
15–44	22.5	2.5	24.0	1.7	25.5	2.5	3.0	0.4
45–54	12.7	1.0	12.9	0.7	13.0	0.9	0.2	0.9
55–64	8.2	0.5	9.8	0.4	11.7	0.6	3.5	<0.0001
65–74	6.8	0.4	7.8	0.3	8.9	0.4	2.1	<0.0001
Sex*								
Male	9.0	0.4	10.0	0.3	11.1	0.4	2.1	0.0001
Female	10.6	0.5	12.0	0.4	13.6	0.6	3.0	<0.0001
Stage*								
Localized	40.6	3.9	42.3	2.5	44.1	3.8	3.5	0.6
Regional	12.0	0.9	15.4	0.7	19.3	1.0	7.3	<0.0001
Distant	4.8	0.4	5.2	0.3	5.7	0.4	0.9	0.1
Unknown	11.1	0.5	11.6	0.4	12.2	0.5	1.1	0.1
Morphology*								
Endocrine (all)	53.1	3.3	51.3	1.8	49.4	2.9	−3.6	0.5
Exocrine (all)	7.8	0.3	8.7	0.2	9.8	0.3	2.0	<0.0001
Subsite (ICD-10)*								
Head (C25.0)	9.2	0.4	10.8	0.3	12.6	0.5	3.5	<0.0001
Body (C25.1)	7.7	1.0	10.1	0.9	13.0	1.2	5.3	0.0005
Tail (C25.2)	12.1	1.1	13.3	0.9	14.4	1.1	2.3	0.1
Overlapping lesions (C25.8)	7.5	1.5	9.6	1.3	12.0	1.9	4.5	0.04
Pancreas, NOS (C25.9)	8.8	0.6	8.4	0.4	8.1	0.5	−0.7	0.3

Comparison of patient population, surgical resection, and outcome in pancreatic cancer patients among European countries

Masoud Babaei

Lei HUANG

Department of Clinical Epidemiology and Aging Research
(C070), DKFZ, Heidelberg, Germany

Aims

- To examine surgical resection rates & outcomes
(3 months, 1-year, 2-year & longer term)
- To study diagnostic **verification** methods
- To compare patterns and effects of **neoadjuvant** and **adjuvant** therapies
- To identify *modifiable areas* for improved outcomes

Data inclusion

- Excel sheet lists demanded variables
- Different data structures among partners adopted accordingly
- Collected from [the earliest year to 2016](#) / latest year with available data
- Major: pancreatic ductal adenocarcinoma (**PDAC**)

Vital status information

- Important & necessary for valid results
- Desirable: national /regional death registration information, official population registers
- Defined index date (end of the last study year with data)
- Partners: description of **data source** required

Expected participants

National & regional cancer databases from partners
+
High volume hospital with available data

Current data sources

- **Netherlands**
- **Norway**
- **NCT-Heidelberg**
- **Italy**
- **Portugal**
- **PanGenEU**
- More to come.....
- Your further support will be highly appreciated!!

Preliminary results:

Parameter	Norway	Portugal
Data type	Population-based	Institution-based
Total #	9123	212
Gender		
<i>Female</i>	4777 (52)	95 (45)
<i>Male</i>	4346 (48)	117 (55)
Age (median, range [year])	73.0 ± 11.8	70 ± 12.1
Age group (year)		
≤ 59	1316 (14)	36 (18)
60-69	2127 (23)	60 (31)
70-79	2775 (30)	72 (37)
≥ 80	2905 (32)	27 (14)
Missing	0 (0)	17 (8)
Method of diagnosis		
<i>Pathology</i>	6476 (71)	14 (7)
<i>Computed tomography</i>	2110 (23)	103 (49)
<i>DCO</i>	536 (6)	0 (0)
<i>Unknown/Others</i>	1 (0)	95 (44)
Differentiation grade		
<i>Well differentiated</i>	240 (8.2)	6 (12)
<i>Intermediately differentiated</i>	1363 (47)	28 (57)
<i>Poorly differentiated</i>	1239 (42)	14 (29)
<i>Undifferentiated</i>	79 (3)	1 (2)
Missing	6202 (68)	163 (76)


Parameter	Norway	Portugal
Clinical T stage		
1	376 (13)	2 (3)
2	720 (24)	13 (11)
3	905 (31)	27 (24)
4	952 (32)	72 (63)
Missing	6170 (68)	98 (36)
Clinical N stage		
0	860 (44)	23 (28)
1	1115 (56)	59 (72)
Missing	7148 (78)	130 (61)
Clinical M stage		
0	1088 (40)	36 (25)
1	1638 (60)	106 (75)
Missing	6397 (70)	70 (33)
Clinical TNM stage		
I	319 (12)	2 (1)
II	193 (7)	4 (3)
III	461 (18)	39 (26)
IV	1638 (63)	106 (70)
Missing	6512 (71)	61 (29)
Surgery		
Yes	1053 (11)	51 (24)
No	8070 (89)	161 (76)

Primary analysis-Resected only

Parameter	Norway	Parameter	Norway	Parameter	Norway
<i>n</i>	1053	Clinical T stage		Interval between diagnosis and surgery (month)	0.2 ± 0.9 (8070)
Gender		1	61 (11.9)	Surgery	
Female	503 (47.8)	2	193 (37.6)	Yes	1053 (11.5)
Male	550 (52.2)	3	220 (42.9)	No/Missing	8070 (88.5)
Age (median, range [year])	73.0 ± 11.8 (0)	4	39 (7.6)	Postsurgical survival (month)	19.4 ± 17.8 (8276)
Age group (year)		Missing	540 (52)	Overall survival (month)	7.4 ± 10.6 (1814)
≤ 59	276 (26.2)	Clinical N stage		Vital status	
60-69	374 (35.5)	0	258 (54.2)	Deceased	859 (81.6)
70-79	342 (32.5)	1	218 (45.8)	Alive	194 (18.4)
≥ 80	61 (5.8)	Missing	577 (55)	Moved	0
Method of diagnosis		Clinical M stage		Cause of death	
Pathology	1053 (100.0)	0	398 (93.4)	Cancer	748 (94.6)
Computed tomography	0	1	28 (6.6)	Non-cancer	43 (5.4)
DCO	0	Missing	627 (64)	Missing	262 (25)
Unknown	0	Clinical TNM stage			
Differentiation grade		1	142 (49.5)		
Well differentiated	57 (6.6)	2	85 (29.6)		
Intermediately	542 (62.5)	3	32 (11.2)		
Poorly differentiated	260 (30.0)	4	28 (9.8)		
Undifferentiated	8 (0.9)	Missing	766 (73)		
Missing	186 (18)				

Norway


Total cases



Surgery



Survival of pancreatic cancer patients who underwent surgery compared with those without surgery



More survival analyses to come: Surgery vs. non-surgery according to TNM stage, location, age group, histology types.....

Acknowledgements

- Prof. H. Brenner & Dr. P. Schrotz-King
- All C070 members
- All partners

Thanks for attention

